Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AVPR1B | P47901 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.39 |
| ▸ | FABP1 | P07148 | 4/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5420923 | 0.91 | LMNA (0.44) | AVPR1BALDH1A1ALOX15LMNAMAPK1 | |
| SCHEMBL16857952 | 0.86 | GAA (0.48) | AVPR1BALDH1A1ALOX15LMNAMAPK1 | |
| SCHEMBL5578367 | 0.84 | AVPR1B (0.46) | AVPR1BALDH1A1L3MBTL1KMT2A | |
| SCHEMBL5578461 | 0.80 | GAA (0.46) | AVPR1BALDH1A1ALOX15LMNAMAPK1 | |
| SCHEMBL5422293 | 0.72 | AVPR1B (0.64) | AVPR1BLMNAMAPK1MAPTSMN1; SMN2 | |
| SCHEMBL5422296 | 0.68 | AVPR1B (0.67) | AVPR1BALDH1A1ALOX15KMT2A | |
| SCHEMBL16857966 | 0.67 | MAPT (0.44) | ALDH1A1LMNAMAPK1MAPTSMN1; SMN2 | |
| SCHEMBL5420928 | 0.66 | AVPR1B (0.65) | AVPR1BLMNAMAPK1MAPTKMT2A | |
| SCHEMBL16672280 | 0.63 | AVPR1B (0.42) | AVPR1BALDH1A1LMNAMAPTSMN1; SMN2 | |
| SCHEMBL1466131 | 0.63 | AVPR1B (0.65) | AVPR1BALDH1A1POLBKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1667993-B1 | HETEROARYL-SUBSTITUTED 1,3-DIHYDROINDOL-2-ONE DERIVATIVES AND MEDICAMENTS CONTAINING THEM | ABBVIE DEUTSCHLAND (DE) | 2015-07-01 | — | — | EP | claimed |
| US-20170050959-A1 | HETEROARYL-SUBSTITUTED 1,3-DIHYDROINDOL-2-ONE DERIVATIVES AND MEDICAMENTS CONTAINING THEM | ABBVIE DEUTSCHLAND (DE) | 2017-02-23 | — | — | US | disclosed |
| US-9487505-B2 | Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them | AbbVie Deutschland GmbH & Co. KG (DE) | 2016-11-08 | — | — | US | disclosed |
| EP-1667993-B1 | HETEROARYL-SUBSTITUTED 1,3-DIHYDROINDOL-2-ONE DERIVATIVES AND MEDICAMENTS CONTAINING THEM | ABBVIE DEUTSCHLAND (DE) | 2015-07-01 | — | — | EP | disclosed |
| US-20140187543-A1 | HETEROARYL-SUBSTITUTED 1,3-DIHYDROINDOL-2-ONE DERIVATIVES AND MEDICAMENTS CONTAINING THEM | AbbVie Deutschland GmbH & Co. KG (DE) | 2014-07-03 | — | — | US | disclosed |
| US-8580842-B2 | Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them | ABBOTT GMBH & CO. KG (DE) | 2013-11-12 | — | — | US | disclosed |
| EP-2546251-A1 | Heteroaryl-substituted 1,3 dihydroindol-2-one derivatives and medicaments containing them | Abbott GmbH & Co. KG (DE) | 2013-01-16 | — | — | EP | disclosed |
| EP-2546250-A1 | Heteroaryl-substituted 1,3 dihydroindol-2-one derivatives and medicaments containing them | Abbott GmbH & Co. KG (DE) | 2013-01-16 | — | — | EP | disclosed |
| EP-2546252-A1 | Heteroaryl-substituted 1,3 dihydroindol-2-one derivatives and medicaments containing them | Abbott GmbH & Co. KG (DE) | 2013-01-16 | — | — | EP | disclosed |
| US-8350055-B2 | Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them | ABBOTT GMBH & CO. KG (DE) | 2013-01-08 | — | — | US | disclosed |
| US-20070185126-A1 | Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing Them | AbbVie Deutschland GmbH & Co. KG (DE) | 2007-08-09 | — | — | US | disclosed |
| US-20070021607-A1 | Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them | ABBOTT GMBH & CO. KG. | 2007-01-25 | — | — | US | disclosed |
| US-20050070718-A1 | Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them | ABBOTT GMBH & CO. KG | 2005-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050070718-A1 | Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them | OXTR, AVPR2, AVPR1A | AVPR1B 4/4885ALDH1A1 886/4885ALOX15 2753/4885 |
| US-20070021607-A1 | Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them | OXTR, AVPR2, AVPR1A | AVPR1B 4/4885ALDH1A1 886/4885ALOX15 2753/4885 |
| US-20140187543-A1 | HETEROARYL-SUBSTITUTED 1,3-DIHYDROINDOL-2-ONE DERIVATIVES AND MEDICAMENTS CONTAINING THEM | OXTR, AVPR2, AVPR1A | AVPR1B 4/4885ALDH1A1 886/4885ALOX15 2753/4885 |
| US-20070185126-A1 | Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing Them | OXTR, AVPR2, AVPR1A | AVPR1B 4/4885ALDH1A1 920/4885ALOX15 2639/4885 |
| US-20170050959-A1 | HETEROARYL-SUBSTITUTED 1,3-DIHYDROINDOL-2-ONE DERIVATIVES AND MEDICAMENTS CONTAINING THEM | OXTR, AVPR2, AVPR1A | AVPR1B 4/4885ALDH1A1 886/4885ALOX15 2753/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.